Bridging Formulations of Quetiapine for Children with Schizophrenia or Bipolar Disorder
Quetiapine is an atypical antipsychotic for treating schizophrenia, bipolar depression, bipolar mania that helps to restore the balance of certain natural substances (neurotransmitters) in the brain. Changing the formulation of quetiapine, originally approved as an immediate release (IR) formulation, given twice per day, to a daily extended release (XR) delivery was undertaken to improve patient adherence. The Simcyp Advanced, Dissolution, Absorption and Metabolism (ADAM) module was used to compare exposure between the two formulations. The modeling showed differences in regional distribution, with most of drug in the IR formulation being absorbed in the duodenum and jejunim, while the XR formulation was releasing further down the intestine and being absorbed in the colon.